Gland Pharma Shares Surge on Securing USFDA Approval for Acetaminophen Injection

Gland Pharma Limited has secured approval from the U.S. Food and Drug Administration (USFDA) for its Acetaminophen Injection. This pain-relief medication will be available in two dosages and is set for market launch soon.

Details of Acetaminophen Injection

This product comes in two dosages: 500 mg/50 mL and 1000 mg/100 mL, and it is equivalent to a similar drug by B. Braun Medical, Inc. The injection is used to relieve mild to moderate pain in adults and children aged two years and older. It can also be used with opioid medications for more severe pain.

Expected Market Launch and Sales 

Gland Pharma plans to introduce this injection through a marketing partner soon. According to IQVIA data, this product had sales of approximately $55 million in the U.S. for the 12 months ending in February 2025.

About Gland Pharma

Founded in 1978 in Hyderabad, Gland Pharma has grown from a contract manufacturer to a global leader in injectable medicines. The company operates in over 60 countries, including the U.S., Europe, Canada, Australia and India. It primarily follows a business-to-business (B2B) model, specialising in various injectables such as vials, ampoules, pre-filled syringes and ophthalmic solutions. It also pioneered Heparin technology in India.

Share performance 

As of April 03 2025, at 12:00 PM, Gland Pharma share price is trading at ₹1,597.95 per share, reflecting a profit of 4.09% from the previous day’s closing price. Over the past month, the stock has registered a profit of 3.84%. The stock’s 52-week high stands at ₹2,220.95 per share, while its low is ₹1,411.10 per share.

Conclusion

The approval strengthens Gland Pharma’s presence in the U.S. pharmaceutical market. Future growth will depend on a successful product launch and industry developments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.